Stada has described the launch of its Movymia (teriparatide) biosimilar in EU markets as a “success” and says doctors and patients alike have “reacted very positively” to the product’s reusable applicator pen.
Having in-licensed the biosimilar osteoporosis therapy from fellow European heavyweight Gedeon Richter, Stada introduced Movymia upon patent expiry in late...






